TypeName: Business Offer
Country: United States
Summary: CB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
https://www.bocsci.com/cb-839-cas-1439399-58-2-item-462472.html
Description: We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.
OfferId: 2231
Name:Alex Brown
Telphone:
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
